TLK 286

Known as: TLK-286, TLK286 
A modified glutathione analog. TLK286 is selectively activated by glutathione S-Transferase P1-1 into an alkylating metabolite which forms covalent… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2013
024620022013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Canfosfamide (TLK286, TELCYTA) is a prodrug that upon activation by glutathione transferase P1-1 (GST P1-1) yields an anticancer… (More)
Is this relevant?
2009
2009
RATIONALE Canfosfamide HCl (CAN) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and… (More)
Is this relevant?
Review
2005
Review
2005
Telik, Inc. (Palo Alto, CA, USA) is currently developing TLK-286, a novel prodrug that is preferentially activated by glutathione… (More)
Is this relevant?
2005
2005
The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA(TM)), a glutathione analog prodrug, in… (More)
Is this relevant?
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
TLK 286 [TELCYTA] is an antitumour agent in clinical development with Telik. It was developed through the application of Telik's… (More)
Is this relevant?
Review
2004
Review
2004
Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer. 
Is this relevant?
2004
2004
PURPOSE To determine the dose-limiting toxicities, maximum tolerated dose, and pharmacokinetics of TLK286, a novel cancer prodrug… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
PURPOSE The purpose of this study was to determine the dose-limiting toxicities (DLTs), the maximum tolerated dose, and the… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2002
2002
Human ovarian carcinoma cells (C70 and C200) made resistant to cisplatin from A2780 cells demonstrated an approximately 20-fold… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
Human ovarian carcinoma cells (C70 and C200) made resistant to cisplatin from A2780 cells demonstrated an 20-fold resistance to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?